Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 2:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo comparison group Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

nCap Pain Relief Patch vs. Placebo

NCT04753567
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
nCap pain relief patch, Sham Patch
Device
Lead sponsor
nCap Medical
Industry
Eligibility
40 Years to 79 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Sep 26, 2026, 2:30 AM EDT
Completed Phase 3 Interventional

Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Children & Adolescents With Bipolar I Mania

NCT00090311
View directory record Official record
Conditions
Bipolar Disorder
Interventions
quetiapine fumarate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 17 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
32
States / cities
Scottsdale, Arizona • Riverside, California • Sacramento, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Sep 26, 2026, 2:30 AM EDT
Completed Phase 3 Interventional Results available

Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD

NCT03095456
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, COPD, Low Peak Inspiratory Flow Rate (PIFR)
Interventions
Revefenacin, Spiriva Handihaler®, Placebo for Revefenacin, Placebo for Spiriva Handihaler®
Drug · Combination Product
Lead sponsor
Mylan Inc.
Industry
Eligibility
40 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Rock Hill, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Sep 26, 2026, 2:30 AM EDT
Completed Phase 3 Interventional Results available

A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease

NCT02207829
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Umeclidinium, Umeclidinium matching placebo, Tiotropium, Tiotropium matching placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
1,017 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Sep 26, 2026, 2:30 AM EDT
Recruiting Phase 2 Interventional

Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS

NCT07189936
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome, Postural Tachycardia Syndrome (POTS), SARS CoV 2 Infection, Long COVID19
Interventions
To Measure levels of circulating monocyte/ T cell doublets at Baseline, To measure levels of circulating monocyte/ T cell doublets after 28 days of 2 HOBA treatment, To measure levels of circulating monocyte/ T cell doublets after 28 days of Placebo treatment, To Measure Splanchnic venous capacitance after 28 days of Treatment with 2HOBA, To Measure Splanchnic venous capacitance after 28 days of Treatment with Placebo, To Measure Orthostatic Tachycardia after 28 days of Treatment with 2HOBA, To Measure Orthostatic Tachycardia after 28 days of Treatment with Placebo
Drug · Diagnostic Test
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 26, 2026, 2:30 AM EDT
Completed Phase 4 Interventional

Effect of Combination Therapy With Two Drugs (Colesevelam and Ezetimibe) in Patients With High Cholesterol

NCT00185107
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Colesevelam Hydrochloride, Ezetimibe, Simvastatin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
7
States / cities
San Diego, California • Ocala, Florida • Overland Park, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2007 · Synced Sep 26, 2026, 2:30 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Clinical Investigation to Examine Toothpaste Effect on Oral Bacteria

NCT02194621
View directory record Official record
Conditions
Oral Bacteria Levels in the Mouth
Interventions
Total Flavor option 1, Total Flavor option 2, Placebo toothpaste: Crest Cavity Protection toothpaste
Drug
Lead sponsor
Colgate Palmolive
Industry
Eligibility
22 Years to 58 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Sep 26, 2026, 2:30 AM EDT
Completed Not applicable Interventional

Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate

NCT02649478
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone / Salmeterol, Placebo, Advair Diskus 100/50
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
12 Years and older
Enrollment
1,430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
100
States / cities
Glendale, Arizona • Phoenix, Arizona • Surprise, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 26, 2026, 2:30 AM EDT
Completed Phase 2 Interventional Results available

Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

NCT02958865
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
PF-06651600 or Placebo, PF-06700841 or Placebo, PF-06700841, PF-06651600
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
60
States / cities
Dothan, Alabama • Long Beach, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Sep 26, 2026, 2:30 AM EDT
Terminated Phase 2 Interventional

A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06028230
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
SAR444656 (KT-474), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
21
States / cities
Scottsdale, Arizona • Anaheim, California • Fountain Valley, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 26, 2026, 2:30 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)

NCT01854645
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
GFF MDI, GP MDI, FF MDI, Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®), Placebo MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
2,103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
121
States / cities
Andalusia, Alabama • Anniston, Alabama • Athens, Alabama + 118 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Sep 26, 2026, 2:30 AM EDT
Terminated Phase 2 Interventional Results available

Mission Connect Mild Traumatic Brain Injury (TBI) Integrated Clinical Protocol

NCT01013870
View directory record Official record
Conditions
Traumatic Brain Injury, Post-traumatic Stress Disorder
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Sep 26, 2026, 2:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration

NCT01710202
View directory record Official record
Conditions
Major Depressive Disorder, Anxiety Disorders
Interventions
Hydrocortisone
Drug
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2015 · Synced Sep 26, 2026, 2:30 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.

NCT02792231
View directory record Official record
Conditions
Relapsing Multiple Scelrosis
Interventions
Ofatumumab subcutaneous injection, Teriflunomide-matching placebo capsules, Teriflunomide capsule, Matching placebo of ofatumumab subcutaneous injections
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
955 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
59
States / cities
Birmingham, Alabama • Cullman, Alabama • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Sep 26, 2026, 2:30 AM EDT
Completed Phase 4 Interventional Results available

Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) Intolerance

NCT00400400
View directory record Official record
Conditions
Renal Transplantation
Interventions
Enteric-coated mycophenolate sodium (EC-MPS), Mycophenolate mofetil, Placebo to mycophenolate sodium, Placebo to mycophenolate mofetil
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
53
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2011 · Synced Sep 26, 2026, 2:30 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Clinical Outcomes Related to Arthroscopic Rotator Cuff Repair Recovery Using Incrediwear

NCT06669741
View directory record Official record
Conditions
Rotator Cuff Tears, Rotator Cuff Injuries, Rotator Cuff Arthropathy of Left Shoulder (Disorder), Rotator Cuff Arthropathy of Right Shoulder (Disorder), Rotator Cuff Arthropathy of Bilateral Shoulders
Interventions
Placebo, Shoulder Sleeve
Device
Lead sponsor
Texas Bone and Joint
Other
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Denton, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Sep 26, 2026, 2:30 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease

NCT03922711
View directory record Official record
Conditions
Parkinson Disease
Interventions
Pridopidine, Placebo
Drug
Lead sponsor
Prilenia
Industry
Eligibility
30 Years to 85 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Sep 26, 2026, 2:30 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)

NCT01794000
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Prasugrel, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
2 Years to 17 Years
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
20
States / cities
Oakland, California • Palo Alto, California • Hartford, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 26, 2026, 2:30 AM EDT
Terminated Not applicable Interventional Results available

Effect of Guanfacine on the Reversal of Opioid-induced Hyperalgesia (OIH)

NCT02192398
View directory record Official record
Conditions
Chronic Pain
Interventions
Guanfacine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 26, 2026, 2:30 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GTR in Comparison to Copaxone®

NCT01489254
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Glatiramer Acetate (GTR), Glatiramer Acetate (Copaxone®), Placebo
Drug
Lead sponsor
Synthon BV
Industry
Eligibility
18 Years to 55 Years
Enrollment
794 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
7
States / cities
Irvine, California • Port Charlotte, Florida • Sunrise, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Sep 26, 2026, 2:30 AM EDT
Completed Phase 3 Interventional Results available

Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease

NCT00478205
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Aricept (donepezil SR 23 mg), Aricept (donepezil IR 10 mg)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
45 Years to 90 Years
Enrollment
1,467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Hickory, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 10, 2014 · Synced Sep 26, 2026, 2:30 AM EDT
Completed Phase 2 Interventional Results available

Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin

NCT01517373
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, PF-04937319 10 mg, PF-04937319 50 mg, PF-04937319 100 mg, Glimepiride
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
23
States / cities
Roseville, California • San Diego, California • Walnut Creek, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Sep 26, 2026, 2:30 AM EDT
Completed Phase 2 Interventional Results available

To Study GSP 301 in Patients With Seasonal Allergic Rhinitis

NCT02318303
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
GSP 301-1 NS (QD), GSP 301-2 NS (BID), GSP 301 Placebo NS, Olopatadine HCl-1 NS (QD), Olopatadine HCl-2 NS (BID), Mometasone Furoate-1 NS (QD), Mometasone Furoate-2 NS (BID)
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
12 Years and older
Enrollment
1,111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Sep 26, 2026, 2:30 AM EDT
Completed Phase 2 Interventional Results available

GM1 Ganglioside Effects on Parkinson's Disease

NCT00037830
View directory record Official record
Conditions
Parkinson Disease
Interventions
GM1 ganglioside, Placebo
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
39 Years to 85 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 20, 2012 · Synced Sep 26, 2026, 2:30 AM EDT